Figure 1. Timeline (not to scale) of key prostate cancer whole genome sequencing and whole exome sequencing studies ^{19– 26, 27– 30}.

One of these studies included 10 hormone treatment-naïve metastatic tumors (metastatic prostate cancer) ²⁴. *A total of 293 primary tumors were analyzed in this study, but 200 were included in a previous study and not included here ²³. The study by Armenia et al. ²⁶ is a uniform re-analysis of previous whole exome sequencing studies, including many of those listed here. mCRPC, metastatic castration-resistant prostate cancer; mPC, metastatic prostate cancer; TCGA, The Cancer Genome Atlas; WES, whole exome sequencing; WGS, whole genome sequencing.